Processa Pharmaceuticals (PCSA)

Executive Summary

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with high unmet medical needs in oncology and rare diseases. Leveraging a regulatory science-driven approach, the company strategically acquires and in-licenses drug candidates to de-risk development and accelerate timelines. Its pipeline includes promising programs targeting metastatic colorectal cancer, ulcerative necrobiosis lipoidica, and gastroparesis. With a focus on conditions where existing treatments are inadequate, Processa aims to deliver meaningful clinical benefits. The company’s disciplined development strategy and experienced management team position it to navigate regulatory pathways efficiently and create shareholder value.

Upcoming Catalysts (preview)

• Q4 2026Top-line Phase 2 data for PCS-6422 in metastatic colorectal cancer40% success
• Q3 2026FDA feedback on Phase 2 trial design for PCS-6422 in gastroparesis60% success
• Q2 2026Initiation of Phase 2 trial for PCS-499 in ulcerative necrobiosis lipoidica70% success